Filtered By:
Drug: Coumadin
Nutrition: Diets
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 35 results found since Jan 2013.
Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry
CONCLUSIONS: Apixaban might be a reasonable alternative to warfarin in patients with severe renal impairment.PMID:34155848
Source: The Israel Medical Association Journal - June 22, 2021 Category: General Medicine Authors: Avishay Elis Robert Klempfner Chen Gurevitz Ela Gilady Ilan Goldenberg Source Type: research
Commentary: Moving the dial on DOAC use early after cardiac surgery
Atrial fibrillation remains an unsolved complication after cardiac surgery with published rates in the 20-50%1,2. As outlined in a recent STS database analysis3, over 60% of US surgeons still use warfarin rather than switching to direct oral anticoagulants (DOACs) for stroke prophylaxis in this clinical scenario. This trend persists despite the limitations associated with warfarin use, including prolonged and often turbulent early titration in new patients, dietary restrictions, strict monitoring requirements and extensive medication interactions.
Source: Seminars in Thoracic and Cardiovascular Surgery - June 14, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Asishana A. Osho, Gus J. Vlahakes Tags: ADULT – Commentary Source Type: research
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
